Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Change in Acquisitions & Divestments (2018 - 2024)

Q32 Bio's quarterly Change in Acquisitions & Divestments came in at $10.0 million in Q3 2024, up 0.98% quarter-over-quarter from $9.9 million in Q2 2024.

Q32 Bio has reported Change in Acquisitions & Divestments for 6 years, with the latest figure at $10.0 million in Q3 2024.

  • For the quarter ending Q3 2024, Change in Acquisitions & Divestments changed N/A year-over-year to $10.0 million; the trailing twelve-month figure through Jun 2025 stood at $10.0 million (changed 0.0% YoY), and the FY2024 full-year result was $20.0 million, changed N/A from the prior year.
  • Change in Acquisitions & Divestments for Q3 2024 stood at $10.0 million, up from $9.9 million in the prior quarter.
  • The five-year high for Change in Acquisitions & Divestments was $117.0 million in Q1 2020, with the low at $97000.0 in Q1 2024.
  • Average Change in Acquisitions & Divestments over 4 years is $35.8 million, with a median of $28.5 million recorded in 2020.
  • Year-over-year, Change in Acquisitions & Divestments advanced 2.12% in 2020 and slumped 59.09% in 2022.
  • Tracing QTTB's Change in Acquisitions & Divestments over 4 years: stood at $39.0 million in 2020, then grew by 12.82% to $44.0 million in 2021, then tumbled by 59.09% to $18.0 million in 2022, then sank by 44.44% to $10.0 million in 2024.
  • The last three Change in Acquisitions & Divestments figures came in at $10.0 million (Q3 2024), $9.9 million (Q2 2024), and $97000.0 (Q1 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Q32 Bio 162.94 Mn 112.19 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2024 10.00 Mn
Sep 30, 2024 10.00 Mn
Jun 30, 2024 9.90 Mn
Jun 30, 2024 9.90 Mn
Mar 31, 2024 97,000.00
Mar 31, 2024 97,000.00
Dec 31, 2022 18.00 Mn
Dec 31, 2022 18.00 Mn
Jun 30, 2022 8.00 Mn
Jun 30, 2022 8.00 Mn
Mar 31, 2022 39.46 Mn
Mar 31, 2022 39.46 Mn
Dec 31, 2021 44.00 Mn
Dec 31, 2021 44.00 Mn
Sep 30, 2020 39.00 Mn
Sep 30, 2020 39.00 Mn
Jun 30, 2020 72.59 Mn
Jun 30, 2020 72.59 Mn
Mar 31, 2020 117.03 Mn
Mar 31, 2020 117.03 Mn
Dec 31, 2019 12.70 Mn
Dec 31, 2019 12.70 Mn
Sep 30, 2019 56.50 Mn
Sep 30, 2019 56.50 Mn
Jun 30, 2019 72.63 Mn
Jun 30, 2019 72.63 Mn
Mar 31, 2019 114.60 Mn
Mar 31, 2019 114.60 Mn
Dec 31, 2018 39.00 Mn
Dec 31, 2018 39.00 Mn
Sep 30, 2018 48.26 Mn
Sep 30, 2018 48.26 Mn
Jun 30, 2018 34.95 Mn
Jun 30, 2018 34.95 Mn
Mar 31, 2018 26.27 Mn
Mar 31, 2018 26.27 Mn